Brief: OliX Pharmaceuticals Inc - Announces Results From Preclinical Study Of Hair Loss Therapeutic Candidate
10/02/2021 23:13
Feb 10 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* OLIX PHARMACEUTICALS INC - ANNOUNCES RESULTS FROM
PRECLINICAL
STUDY OF HAIR LOSS THERAPEUTIC CANDIDATE
* OLIX PHARMACEUTICALS INC - PLAN TO INITIATE CLINICAL
TRIALS OF
ITS INVESTIGATIONAL RNAI THERAPEUTIC IN DEVELOPMENT FOR HAIR
LOSS BY 2022
* OLIX PHARMACEUTICALS INC - DEMONSTRATED EFFICACY IN A
PRECLINICAL STUDY OF ITS INVESTIGATIONAL RNAI THERAPEUTIC IN
DEVELOPMENT FOR HAIR LOSS
Source text for Eikon: ID:nGNX2kN1sL
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment